Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Sponsors › Genomics: Clinical Implementation › Poised to Join Complex Market, Exosome Dx Publishes Validation Data for EGFR T790M Assay

Poised to Join Complex Market, Exosome Dx Publishes Validation Data for EGFR T790M Assay

Apr 02, 2018
|
Molika Ashford
Premium

NEW YORK (GenomeWeb) – Exosome Diagnostics has published a new study validating its exosome-based liquid biopsy assay for EGFR T790M testing in lung cancer patients, suggesting that its approach offers improved sensitivity over the only blood-based platform currently approved by the US Food and Drug Administration for this indication.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

What's Popular?

In Molecular Diagnostics

  1. Illumina to Acquire Grail for $8B in Cash and Stock

  2. Roche's Ipatasertib, Anti-Androgen Therapy Improves Outcomes in Prostate Cancer With PTEN Loss

    Premium

  3. Drug Combination, Biomarker Search Continues in Urothelial Cancer After Mixed ESMO Trial Data

    Premium

  4. HPV, p16 May Offer Different Prognostic Clues in Oropharyngeal Cancer, ESMO Data Reveals

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.